ArticleFrontiers in oncology2026
Eupatilin-derived compounds enhance antitumor activity and doxorubicin efficacy in triple-negative breast cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Triple-negative breast cancer (TNBC) has limited therapeutic options. We evaluated the anticancer activities of the Eupatilin derivatives ONG41008 and ONG41003 and their potential to enhance doxorubicin efficacy. Materials and methods: Anticancer activity was evaluated in TNBC cells using viability, cell-cycle, apoptosis, migration, and invasion assays. Drug interactions with doxorubicin and paclitaxel were assessed using dose-response curves and the Loewe model. Doxorubicin accumulation and ABCB1 and ABCG2 mRNA expression were analyzed. ONG41003 efficacy was further evaluated in an orthotopic TNBC xenograft model. Results: Both derivatives induced G2/M arrest and apoptosis and inhibited migration and invasion. ONG41008 showed an apparent reduction in the fitted doxorubicin IC Conclusion: ONG41008 and ONG41003 exerted anticancer effects and enhanced the response to doxorubicin through distinct interactions. Increased doxorubicin accumulation may be associated with attenuation of ABCB1 expression, supporting further investigation of these compounds as partners for anthracycline-based chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.